Homecare Update
(From the October 2024 Issue of MedStat)
Homecare RSV Season Reminder
The use of single dose nirsevimab (Beyfortus™) for RSV prevention is recommended. The Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) met in June and made no changes to the recommendations for infant prophylaxis with monoclonal antibodies such as nirsevimab. According to the ACIP, “all infants are recommended to be protected by either maternal RSV vaccination or nirsevimab for the 2024-2025 RSV season.”
Resources regarding the use of nirsevimab (Beyfortus™):
- Partners For Kids® (PFK) newsletters have updated information for community providers, accessible online. The updated PFK RSV prevention website includes new tools and resources from American Academy of Pediatrics, CDC and Sanofi.
Additional information and a link to the recording of the webinar with Pablo Sanchez, MD, from September 12, are available at the Homecare webpage under the “Professionals” tab. Please feel free to share this information with your staff and colleagues.
If you have questions regarding services or programs, call (614) 355-1100, Monday through Friday, 8 a.m. to 5 p.m., excluding national holidays, or email Carolyn Figi.